D.J. St. Germain’s Ligand Pharmaceuticals LGND Stock Holding History

D.J. St. Germain’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.7K	Hold	75	–	–	﹤0.01%	564
2026 Q1	$15K	Hold	75	–	–	﹤0.01%	608
2025 Q4	$14.2K	Hold	75	–	–	﹤0.01%	622
2025 Q3	$13.3K	Hold	75	–	–	﹤0.01%	617
2025 Q2	$8.53K	Hold	75	–	–	﹤0.01%	672
2025 Q1	$7.89K	Hold	75	–	–	﹤0.01%	592
2024 Q4	$8.04K	Hold	75	–	–	﹤0.01%	612
2024 Q3	$7.51K	Hold	75	–	–	﹤0.01%	575
2024 Q2	$6.32K	Hold	75	–	–	﹤0.01%	592
2024 Q1	$5.48K	Hold	75	–	–	﹤0.01%	600
2023 Q4	$5.36K	Hold	75	–	–	﹤0.01%	612
2023 Q3	$4.49K	Hold	75	–	–	﹤0.01%	593
2023 Q2	$5.41K	Buy	+75	New	+$5.63K	﹤0.01%	580

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.J. St. Germain's LGND Position: Q2 2026 in Review

D.J. St. Germain held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 75 shares worth $23.7K. The position accounts for ﹤0.01% of the portfolio, ranked #564.

D.J. St. Germain first reported a position in LGND in Q2 2023 and has held it in 13 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

D.J. St. Germain held 75 shares of Ligand Pharmaceuticals worth $23.7K as of Q2 2026.
D.J. St. Germain left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
Ligand Pharmaceuticals made up ﹤0.01% of D.J. St. Germain's portfolio in Q2 2026, its #564 holding.
D.J. St. Germain first reported a position in Ligand Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on D.J. St. Germain's 13F filing for Q2 2026, filed 21 Jul 2026.